Portola Pharma (PTLA) Tops Q3 EPS by 14c, Revenues Beat

Portola Pharma (NASDAQ: PTLA) reported Q3 EPS of ($0.68), $0.14 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $36.8 million versus the consensus estimate of $34.63 million.

"We delivered another quarter of strong Andexxa revenue in the U.S. and expanded our growth potential with our first sales of Ondexxya in Europe. The use of Factor Xa inhibitors in both markets continues to grow, driving the underlying market opportunity for Andexxa/Ondexxya and long-term value of Portola," said Scott Garland, Portola\'s president and chief executive officer. "Looking forward, we will continue to focus on exceptional launch execution, leveraging external support from health authorities and favorable society guidelines, and building the clinical evidence and awareness of Andexxa. In addition, we remain on track to initiate a registration trial for cerdulatinib in early 2020 and will present updated data at the ASH meeting in December."

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M